Andrea Ciolfi
Has grant
Senior Staff Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Definizione di una procedura analitica standardizzata per la reinterpretazione periodica di varianti genomiche nella pratica clinica
Open Date: 2023-01-01
Close Date: 2025-12-01
Grant: Close
Utilizzo di reti neurali per l’identificazione di nuove signature di metilazione di DNA da sangue in pazienti affetti da malattie mendeliane del neurosviluppo.
Open Date: 2022-01-01
Close Date: 2022-12-01
Grant: Close
Sviluppo di nuove tecniche di classificazione automatica di dati epigenomici per pazienti senza diagnosi
Open Date: 2021-01-01
Close Date: 2021-12-01
Articles (13)
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Tubulinopathies encompass a wide spectrum of disorders resulting from variants in genes encoding α- and β-tubulins, the key components of microtubules. While previous studies have linked de novo or dominantly inherited TUBA4A missense variants to neurodegenerative phenotypes, including amyotrophic lateral sclerosis, frontotemporal dementia, hereditary spastic ataxia, and more recently, an isolated report of congenital myopathy, the full phenotypic and genotypic spectrum of TUBA4A -related disorders remains incompletely characterised. In this multi-centre study, we identified 13 novel TUBA4A missense variants in 31 individuals from 19 unrelated families. Remarkably, affected individuals in 17 families presented with a primary axial myopathy without any identified CNS involvement or history of such disease. In the remaining two families, we observed probands with cerebellar ataxia and epilepsy accompanying proximal and axial muscle weakness, establishing the first documented association between TUBA4A variants and multisystem proteinopathy. Our cohort exhibited diverse genotypes and associated inheritance patterns: four families demonstrated autosomal dominant transmission through heterozygous variants in TUBA4A , three probands had homozygous TUBA4A variants, where the biallelic genotype was found to be associated with the disease, and the heterozygous carriers were asymptomatic; five probands carried de novo variants, and nine probands with heterozygous TUBA4A variants were classified as "isolated-sporadic cases" where parental samples were unavailable. Clinical phenotypes ranged from mild to severe myopathy, predominantly affecting the axial and paraspinal muscles. We observed a range of disease onset, from congenital to late adulthood. Creatine kinase levels were also variable, ranging from normal to highly elevated. Cardiac function remained preserved across the cohort. Muscle biopsies revealed a range of pathologies, including myofibre size variation, myofibre atrophy, nemaline bodies, core-like regions, internal nuclei, and endomysial fibrosis. Immunohistochemical staining showed evidence of proteinopathy, with autophagic features and TUBA4A accumulation in patient myofibres. Complementary in silico and in vitro investigations suggested that the identified TUBA4A substitutions cause significant protein abnormalities and may differentially impact microtubule dynamics. Our findings establish myo-tubulinopathies as distinct clinical entities, encompassing both primary myopathies and multisystem proteinopathies with muscle involvement. This study broadens the phenotypic and genotypic spectrum of TUBA4A -related disorders beyond autosomal dominant or de novo mechanisms and neurodegenerative presentations. These results underscore the importance of considering TUBA4A variants in the differential diagnosis of axial myopathies and multisystem proteinopathies, regardless of central nervous system (CNS) involvement.
Year:
2025
Year:
2024
Year:
2024
Key Points Ketogenic diet can change the metabolism in the body and helped restore the function of altered pathways in nephropathic cystinosis. Ketogenic diet had significant benefits for preventing kidney damage, even when initiated after the onset of kidney impairment. Ketogenic diet may provide a partial therapeutic alternative in countries where cysteamine therapy is too expensive. Background Nephropathic cystinosis is a rare inherited lysosomal storage disorder caused by mutations in the CTNS gene that encodes for cystinosin, a lysosomal cystine/H + symporter. From the standpoint of the kidneys, patients develop early-onset renal Fanconi syndrome and progressive CKD. Current therapy with cysteamine delays but does not prevent kidney failure and has significant side effects that limit adherence and reduce the quality of life of patients. Methods We have tested biochemically and histologically the effects of ketogenic diet on kidney disease of two animal models of nephropathic cystinosis. Results When Ctns −/− mice were fed with ketogenic diet from 3 to 12 months of age, we observed significant nearly complete prevention of Fanconi syndrome, including low molecular weight proteinuria, glycosuria, and polyuria. Compared with wild-type animals, BUN at 12 months was higher in cystinotic mice fed with standard diet ( P < 0.001), but not with ketogenic diet. At sacrifice, kidneys of knockout mice fed with ketogenic diet appeared macroscopically similar to those of wild-type animals, which was reflected microscopically by a significant reduction of interstitial cell infiltration (CD3 and CD68 positive cells, P < 0.01), of interstitial fibrosis (Masson and α -smooth muscle actin staining, P < 0.001), and of apoptosis (cleaved caspase-3 levels; P < 0.001), and by indirect evidence of restoration of a normal autophagic flux (SQSTM1/p62 and LC3-II expression, P < 0.05). Beneficial effects of ketogenic diet on tubular function were also observed after mice were fed with this ketogenic diet from the age of 6 months to the age of 15 months, after they had developed proximal tubular dysfunction. Although slightly less pronounced, these results were replicated in Ctns −/− rats fed with ketogenic diet from 2 to 8 months of life. Conclusions These results indicate significant mitigation of the kidney phenotype in cystinotic animals fed with ketogenic diet.
Year:
2024
Malformations of the brain are common and vary in severity, from negligible to potentially fatal. Their causes have not been fully elucidated. Here, we report pathogenic variants in the core protein-folding machinery TRiC/CCT in individuals with brain malformations, intellectual disability, and seizures. The chaperonin TRiC is an obligate hetero-oligomer, and we identify variants in seven of its eight subunits, all of which impair function or assembly through different mechanisms. Transcriptome and proteome analyses of patient-derived fibroblasts demonstrate the various consequences of TRiC impairment. The results reveal an unexpected and potentially widespread role for protein folding in the development of the central nervous system and define a disease spectrum of “TRiCopathies.”
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (49)
Peter Kang
Executive, Administrative, and Managerial Staff, Associate Dean
University of Minnesota
Stefan Barakat
Associate professor
Erasmus MC
Tim Schedl
Professor
Washington University in Saint Louis School of Medicine
Pamela Trapane
Professor and Chief, Division of Pediatric Genetics
University of Florida College of Medicine - Jacksonville
Anna Jansen
University of Antwerp
Carol Saunders
Children's Mercy Hospital
Paulino Gomez-Puertas
Consejo Superior de Investigaciones Cientificas
Olaf Riess
University of Tuebingen
Andreas Roos
-
Ohad S. Birk
-
Matthias Begemann
Medizinische Fakultät der RWTH Aachen
Marco Savarese
University of Helsinki
Sigmar Stricker
Professor
Karl Landsteiner University of Health Sciences
Marco Tartaglia
Head
Ospedale Pediatrico Bambino Gesù
Joachim Weis
Medizinische Fakultät der RWTH Aachen
Martin Wiesmann
University Hospital RWTH Aachen
B. Callewaert
Associate Professor
Ghent University
Zeynep Tumer
Clinical Professor
University of Copenhagen
Stephen Pak
Professor
Washington University in Saint Louis School of Medicine
Chiara Folland
University of Western Australia
Weimin Yuan
Staff scientist
Washington University in St. Louis
Giorgio Tasca
Clinical Prof of Neuromuscular Science
Newcastle University
Sven Geißler
Professor of the Biology of Musculoskeletal Regeneration
Charité - Universitätsmedizin Berlin
Judith Frydman
Professor
Stanford University
Evelina Miele
Associate Medical Director
Ospedale Pediatrico Bambino Gesù
Marije Meuwissen
-
Micheil Innes
Associate Professor
University of Calgary
Gary A Silverman
Chair
Washington University in Saint Louis School of Medicine
Mridul Johari
University of Western Australia
Renske Oegema
UMC Utrecht
Martin Häusler
Head of Division, Prof. Dr. med
RWTH Aachen University
Manfred Gossen
-
Gael Nicolas
PUPH
University of Rouen
David J. Amor
University of Melbourne
Ichizo Nishino
Director
-
Wim Van Paesschen
Professor in Neurology
-
Andrea Maier
-
Hanns Lochmüller
Senior Scientist
-
Alan Beggs
Sir Edwin & Lady Manton Professor
Harvard Medical School
Stefan Wolking
-
Yoshihiko Saito
National Center of Neurology and Psychiatry
Marcello Niceta
Principal Investigator
Ospedale Pediatrico Bambino Gesù
Ingo Kurth
Head of Institute
RWTH Aachen University
Ana Töpf
Senior Research Scientist
Newcastle University
John Vissing
-
Chiara Leoni
MD, PhD
Agostino Gemelli University Polyclinic
Thomas Smol
PU-PH
Université de Lille
Gianina Ravenscroft
University of Western Australia
Yvonne Weber
Leader of the Dpt. of Epileptology/ Prof
RWTH Aachen University
Make your next move.
Prepare your application
Review drafts before you send them.